Wen et al. [17] found that subcutaneous injection of DPSCs could reduce the symptoms of skin lesions in IMQ-induced psoriasis mouse model and suppress the expression of keratin 16, S100A8, and S100A9, which are associated with abnormal epidermal proliferation, indicating the feasibility of DPSCs for the clinical treatment of psoriasis. This evidence concerns the gene KRT16 and psoriasis.